Over expression of other tyrosine kinase receptors such as HER-2, c-MET has also been widely reported in the case of HNSCC enabling resistance towards receptor targeting monoclonal antibody therapies against HNSCC [60]. Here, ERBB2 is linked to head and neck squamous cell carcinoma.